PCI-CURE and CREDO Long-Term Benefits of Clopidogrel in PCI Patients
{"Image DocumentName": "PCI-CURE and CREDO Long-Term Benefits of Clopidogrel in PCI Patients", "Image ImageDescription": "15. Placebo\u2021 Clopidogrel\u2021 Days of follow-up. 12.6% 8.8% P = N = CV-death or MI (%) 31% RRR. Placebo  Clopidogrel  11.5% 27% RRR % MI, Stroke or Death (%) 5. P=0.02. N = In the Clopidogrel for the Reduction of Events during Observation (CREDO) trial, 2116 patients scheduled to undergo percutaneous coronary intervention (PCI) or thought to be at high likelihood of undergoing PCI were randomized to a 300mg loading dose of clopidogrel vs. placebo 3-24 hours prior to PCI. Following PCI, all patients received 75mg daily clopidogrel through day 28. From day 28 through 1 year, patients in the loading dose group received 75mg daily placebo. Clopidogrel reduced the 1-year risk of MI, stroke, or death by 27% (95% confidence interval [CI], 3.9%-44.4%; P =.02; absolute reduction, 3%). No significant difference was seen in 28 day combined risk of MI, death, or urgent target vessel revascularization (risk reduction, 18.5%; 95% CI, -14.2% to 41.8%; P =.23) Months From Randomization. Mehta et al. Lancet 2001;358: Steinhubl S et al. JAMA. 2002; 288: \u2020up to 12 months. \u2021plus ASA and other standard therapies.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}